Nautilus Biotechnology (NAUT) Cash & Current Investments (2020 - 2026)

Nautilus Biotechnology has disclosed Cash & Current Investments across 7 years of filings, most recently posting $95.9 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $95.9 million, down 30.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.9 million (down 30.94% YoY), and the FY2025 annual result was $103.4 million, down 20.39% from the prior year.
• Cash & Current Investments came in at $95.9 million for Q1 2026 at Nautilus Biotechnology, down from $103.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $324.1 million in Q1 2022 to a low of $95.9 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $167.3 million (2023), against an average of $175.9 million.
• Across the five-year window, Cash & Current Investments soared 47423.79% in 2022 and tumbled 48.37% in 2023, its largest moves.
• Nautilus Biotechnology's Cash & Current Investments stood at $184.5 million in 2022, then fell by 5.99% to $173.4 million in 2023, then decreased by 25.1% to $129.9 million in 2024, then decreased by 20.39% to $103.4 million in 2025, then retreated by 7.29% to $95.9 million in 2026.
• The last three Cash & Current Investments figures came in at $95.9 million (Q1 2026), $103.4 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.